Secretory phospholipase A2 of group IIA: Is it an offensive or a defensive player during atherosclerosis and other inflammatory diseases?

Prostaglandins and Other Lipid Mediators

Volumn 79, Issue 1-2, 2006, Pages 1-33

  Menschikowski, Mario ^a   Hagelgans, Albert ^a   Siegert, Gabriele ^a  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

Atherosclerosis; HMG CoA reductase inhibitors; Inflammation; Secretory phospholipase A2; Sepsis; Statins

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; C REACTIVE PROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LY 333013; PHOSPHOLIPASE A2; PHOSPHOLIPASE A2 INHIBITOR; RECOMBINANT ENZYME; UNCLASSIFIED DRUG; VARESPLADIB; ENZYME INHIBITOR; GROUP II SECRETORY PHOSPHOLIPASE A2; PHOSPHOLIPASE A;

ANTIBACTERIAL ACTIVITY; ANTICOAGULATION; ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; ATHEROGENESIS; ATHEROSCLEROSIS; BLOOD LEVEL; CLINICAL TRIAL; DISEASE PREDISPOSITION; DOSE RESPONSE; DRUG POTENTIATION; ENZYME INDUCTION; ENZYME INHIBITION; ENZYME LOCALIZATION; ENZYME SPECIFICITY; HUMAN; INFLAMMATORY DISEASE; LIPOPROTEIN METABOLISM; NONHUMAN; PROTEIN FUNCTION; REVIEW; RHEUMATOID ARTHRITIS; SEPSIS; UPREGULATION; ADRENAL GLAND; ANIMAL; DRUG ANTAGONISM; DRUG EFFECT; ENZYMOLOGY; GENE EXPRESSION REGULATION; INFLAMMATION; LIVER; METABOLISM; PATHOLOGY;

ADRENAL GLANDS; ANIMALS; ATHEROSCLEROSIS; ENZYME INHIBITORS; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; INFLAMMATION; LIVER; PHOSPHOLIPASES A; SEPSIS; UP-REGULATION;

EID: 33644550312     PISSN: 10988823     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.prostaglandins.2005.10.005     Document Type: Review

References (383)

1. M. Waite The phospholipases D.J. Hanahan Handbook of lipid research vol. 5 1987 Plenum New York 1
2. A.R. Poole, J.I. Howell, and J.A. Lucy Lysolecithin and cell fusion Nature 227 1970 810
3. M.T. Quinn, S. Parthasarathy, and D. Steinberg Lysophosphatidylcholine: a chemotactic factor for human monocytes and its potential role in atherogenesis Proc Natl Acad Sci USA 85 1988 2805
4. 2 and their receptors and binding proteins Biochim Biophys Acta 1488 2000 59
5. 2 enzymes: classification and characterization Biochim Biophys Acta 1488 2000 1
6. 2 enzymes Prostaglandins Other Lipid Mediat 68 2002 3
7. 2 superfamily of signal transduction enzymes Trends Biochem Sci 22 1997 1
8. 2 J Biol Chem 273 1998 14411
9. 2 from peritoneal cavity of caseinate-treated rat J Biochem (Tokyo) 102 1987 147
10. 2 J Biol Chem 264 1989 5768
11. 2 present in rheumatoid arthritic synovial fluid J Biol Chem 264 1989 5335
12. 2 in the pathobiology of disease Lab Invest 55 1986 391
13. 2 - a mediator between proximal and distal effectors of inflammation Immunol Today 12 1991 143
14. C. Waydhas, D. Nast-Kolb, K.H. Duswald, P. Lehnert, and L. Schweiberer Prognostic value of serum phospholipase A in the multitraumatized patient Klin Wochenschr 67 1989 203
15. 2 activity in sera and synovial fluids in rheumatoid arthritis and osteoarthritis. Its possible role as a proinflammatory enzyme J Rheumatol 12 1985 211
16. 2 Crit Rev Immunol 17 1997 225
17. 2 J Immunol 166 2001 4029
18. 2 against Staphylococcus aureus J Immunol 162 1999 7402
19. 2 to Escherichia coli infection Infect Immun 68 2000 87
20. 2 in serum of patients with bacterial infections J Infect Dis 185 2002 1767
21. 2 J Biol Chem 277 2002 5849
22. 2 against Staphylococcus aureus J Biol Chem 277 2002 47636
23. 2 against grossly clumped Staphylococcus aureus Infect Immun 67 1999 2299
24. 2 against Bacillus anthracis and inhibition of its secretion by the lethal toxin J Immunol 173 2004 521
25. 2 against Pseudomonas aeruginosa clinical isolates J Med Microbiol 52 2003 1039
26. 2, fails to improve clinical outcome for patients with severe sepsis Crit Care Med 33 2005 1741
27. 2 in human aortic smooth muscle cells and HepG2 hepatoma cells Biochim Biophys Acta 1733 2005 157
28. C. Bustos, M.A. Hernandez-Presa, and M. Ortego HMG-CoA reductase inhibition by atorvastatin reduces neointimal inflammation in a rabbit model of atherosclerosis J Am Coll Cardiol 32 1998 02057
29. S. Takeuchi, S. Kawashima, and Y. Rikitake Cerivastatin suppresses lipopolysaccharide-induced ICAM-1 expression through inhibition of Rho GTPase in BAEC Biochem Biophys Res Commun 269 2000 97
30. H. Kothe, K. Dalhoff, and J. Rupp Hydroxymethylglutaryl coenzyme A reductase inhibitors modify the inflammatory response of human macrophages and endothelial cells infected with Chlamydia pneumoniae Circulation 101 2000 1760
31. 2 formation in renal mesangial cells Biochim Biophys Acta 1636 2004 108
32. Scandinavian Simvastatin Survival Study Group Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) Lancet 344 1994 1383
33. J. Shepherd, S.M. Cobbe, and I. Ford Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group N Engl J Med 333 1995 1301
34. F.M. Sacks, M.A. Pfeffer, and L.A. Moye The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators N Engl J Med 335 1996 1001
35. A.M. Gotto Jr. Ongoing clinical trials of statins Am J Cardiol 88 2001 36F
36. P.T. Ma, G. Gil, T.C. Sudhof, D.W. Bilheimer, J.L. Goldstein, and M.S. Brown Mevinolin, an inhibitor of cholesterol synthesis, induces mRNA for low density lipoprotein receptor in livers of hamsters and rabbits Proc Natl Acad Sci USA 83 1986 8370
37. U. Laufs, V. La Fata, J. Plutzky, and J.K. Liao Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors Circulation 97 1998 1129
38. U. Laufs, and J.K. Liao Post-transcriptional regulation of endothelial nitric oxide synthase mRNA stability by Rho GTPase J Biol Chem 273 1998 24266
39. 2s Adv Immunol 77 2001 163
40. 2 Biochim Biophys Acta 1214 1994 88
41. 2 in mononuclear phagocytic cells in rat spleen and liver Eur J Biochem 197 1991 323
42. 2 released from rat platelets J Biochem (Tokyo) 101 1987 625
43. 2 from activated mast cells and its possible involvement in the regulation of the degranulation process Eur J Biochem 209 1992 257
44. 2 in human tissue Inflammation 17 1993 453
45. 2 (type II) in human placenta and its possible involvement in normal parturition at term Prostaglandins Leukot Essent Fatty Acids 51 1994 19
46. 2 in human seminal plasma Biochem Biophys Res Commun 178 1991 1505
47. 2 in human seminal plasma Andrologia 25 1993 355
48. 2 by lacrimal gland Invest Ophthalmol Vis Sci 32 1994 417
49. 2 and prostaglandins in human seminal plasma Adv Prostaglandin Thromboxane Res 3 1978 159
50. M. Riffo, and M. Parraga Lysophosphatidylcholine treatment allows interspecies fertilization of hamster oocytes with zona pellucida by human spermatozoa J Exp Zool 271 1995 151
51. 2 in rat Paneth cells Histochemistry 81 1984 581
52. 2 in the human gastrointestinal tract Lab Invest 72 1995 201
53. R. Homan, and M.K. Jain C.M. Mansbach P. Tso A. Kuksis Intestinal lipid metabolism 2001 Kluwer Academic New York 81
54. 2-deficient mice Gastroenterology 120 2001 1193
55. 2 gene in inbred mouse strains J Biol Chem 270 1995 22378
56. 2 in human gestational tissues: subcellular distribution of placental immuno- and catalytic activity Biochim Biophys Acta 1166 1993 77
57. 2 isozymes in pregnancy and parturition Prostaglandins Leukot Essent Fatty Acids 70 2004 87
58. 2 levels: correlation with hemodynamic and pulmonary changes in Gram-negative septic shock J Lab Clin Med 104 1984 873
59. 2 activity associated with sepsis and septic shock is indistinguishable from that associated with rheumatoid arthritis Inflammation 15 1991 355
60. 2 expression and pathogenesis of the sepsis syndrome Circ Shock 39 1993 160
61. 2 in human acute pancreatitis Gastroenterology 97 1989 1521
62. 2 in intensive care patients with peritonitis, multiple injury, and necrotizing pancreatitis Klin Wochenschr 67 1989 217
63. 2, C-reactive protein, and white blood cell count in the diagnosis of acute appendicitis Clin Chem 40 1994 1757
64. 2 levels correlate with disease activity in rheumatoid arthritis J Rheumatol 15 1988 1351
65. 2 levels in patients with advanced cancer Clin Chim Acta 228 1994 91
66. 2. Basic and clinical aspects in inflammatory diseases 1997 Karger Basel 200
67. 2 increases with prostate tumor grade Clin Cancer Res 7 2001 3857
68. 2 is elevated in prostatic intraepithelial neoplasia and adenocarcinoma Am J Pathol 160 2002 667
69. 2 gene is a candidate for the Mom1 locus, a major modifier of ApcMin-induced intestinal neoplasia Cell 81 1995 957
70. 2 gene alterations in human colorectal cancer Cancer Res 55 1995 5184
71. 2 in prostate cancer Cancer Res 64 2004 6934
72. 2 in prostate cancer. Cancer Lett, 2005; in press.
73. 2 in cardiovascular disease: a mediator in atherosclerosis and ischemic damage to cardiomyocytes? Cardiovasc Res 60 2003 68
74. 2 binds to ischemic flip-flopped cardiomyocytes and subsequently induces cell death Am J Physiol Heart Circ Physiol 285 2003 H2218
75. 2 in the central nervous system: implications for neurodegenerative diseases J Lipid Res 45 2004 205
76. 2 Neurochem Res 29 2004 1961
77. 2 in astrocytes: responses to oxidative stress, inflammation, and G protein-coupled receptor agonists Mol Neurobiol 31 2005 27
78. 2 J Biol Chem 266 1991 14119
79. 2 in rat cultured astrocytes. Two distinct pathways of the gene expression J Biol Chem 266 1991 9956
80. 2 by rat mesangial cells. Its contribution to arachidonic acid release and prostaglandin synthesis by cultured rat glomerular cells J Clin Invest 92 1993 2516
81. 2 Biochim Biophys Acta 1170 1993 217
82. 2 J Lipid Mediat Cell Signal 12 1995 119
83. 2 gene expression in human hepatoma cells by mediators of the acute phase response J Biol Chem 266 1991 2647
84. 2. Basic and clinical aspects in inflammatory diseases 1997 Karger Basel 104
85. 2 in human serum Clin Chem 38 1992 1824
86. 2 and demonstration of postoperative elevation Enzyme 45 1991 200
87. 2 detected by a radioimmunoassay is a sensitive marker of inflammation in rheumatoid arthritis Res Commun Chem Pathol Pharmacol 76 1992 279
88. 2 in serum in critically ill surgical patients Crit Care Med 22 1994 956
89. 2 gene in vascular smooth muscle cells by a nuclear factor κB and peroxisome proliferators-activated receptor-mediated process J Biol Chem 274 1999 23085
90. 2 in cultured rat astrocytes J Biol Chem 275 2000 10876
91. Z.J. Tian, and W. An ERK1/2 contribures negative regulation to STAT3 activity in HSS-transfected HepG2 cells Cell Res 14 2004 141
92. J. Darnell Jr., I. Kerr, and G. Stark Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins Science 264 1994 1415
93. T.K. Held, X. Weihua, L. Yuan, D.V. Kalvakolanu, and A.S. Cross Gamma interferon augments macrophage activation by lipopolysaccharide by two distinct mechanisms, at the signal transduction level and via an autocrine mechanism involving tumor necrosis factor-α and interleukin-1 Infect Immun 67 1999 206
94. M. Hiroi, and Y. Ohmori The transcriptional coactivator CREB-binding protein cooperates with STAT1 and NF-κB for synergistic transcriptional activation of the CXC ligand 9/monokine induced by interferon-γ gene J Biol Chem 278 2003 651
95. 2 Am J Pathol 134 1989 807
96. 2 exacerbates poly-l-arginine induced rat paw edema Inflammation 18 1994 59
97. 2 induces a synovitis-like inflammation in the rat air pouch J Rheumatol 21 1994 824
98. 2 induces an inflammatory response in rabbit joints J Immunol 146 1991 3904
99. 2 FEBS Lett 281 1990 113
100. 2 lacks edema producing activity in rat Eur J Pharmacol 235 1993 45
101. 2 in transgenic mice results in epidermal hyperplasia in the absence of inflammatory infiltrate J Clin Invest 97 1996 2233
102. 2 in transgenic mice J Histochem Cytochem 45 1997 1109
103. 2 inhibitors Eur J Pharmacol 308 1996 195
104. 2. Basic and clinical aspects in inflammatory diseases 1997 Prog Surg Basel 65
105. P. Rayer Memoires sur lòssification morbide, considerce comme une terminaison des phlegmasics Arch Gen Med 1 1823 31
106. R. Virchow Der atheromatöse prozess der arterien Wien Med Wochenschr 6 1856 825
107. R. Ross, and J.A. Glomset The pathogenesis of atherosclerosis (first of two parts) N Engl J Med 295 1976 369
108. R. Ross, and J.A. Glomset The pathogenesis of atherosclerosis (second of two parts) N Engl J Med 295 1976 420
109. J. Joris, and G. Manjo Atherosclerosis and inflammation Adv Exp Med Biol 104 1977 227
110. J.M. Munro, and R.S. Cotran The pathogenesis of atherosclerosis: atherogenesis and inflammation Lab Invest 58 1988 249
111. R. Ross The pathogenesis of atherosclerosis: a perspective for the 1990s Nature 362 1993 801
112. A.C. van der Wal, A.E. Becker, C.M. van der Loos, and P.K. Das Site of intimal rupture or erosion of thrombosed coronary atherosclerotic plaques is characterized by an inflammatory process irrespective of the dominant plaque morphology Circulation 89 1994 36
113. R.W. Alexander Inflammation and coronary artery disease N Engl J Med 331 1994 468
114. R. Ross Atherosclerosis - an inflammatory disease N Engl J Med 340 1999 115
115. 2 in human atherosclerotic plaques Atherosclerosis 118 1995 173
116. 2 expression in human aortic tissue in dependence on the degree of atherosclerosis Atherosclerosis 144 1999 73
117. 2 in relation to the presence of microbial agents, macrophage infiltrates, and transcripts of proinflammatory cytokines in human aortic tissues Arterioscler Thromb Vasc Biol 20 2000 751
118. 2 in human monocyte-derived macrophages Arterioscler Thromb Vasc Biol 20 2000 1276
119. 2 increases atherosclerotic lesion formation in LDL receptor-deficient mice Arterioscler Thromb Vasc Biol 23 2003 263
120. 2 by CD1a positive cells-in human atherosclerotic plaques Atherosclerosis 127 1996 283
121. S.G.E. Barker, A. Talbert, and S. Cottam Arterial intimal hyperplasia follows occlusion of the adventitial vasa vasorum in the pig Arterioscler Thromb 13 1993 70
122. S.G.E. Barker, and J.F. Martin Role of the adventitia in the atherogenesis: arterial wall vasa vasorum P. Woodford Atherosclerosis X, Proceedings of the 10th International Symposium on Atherosclerosis, October 9-14, 1994 1995 Elsevier Montreal 926
123. 2 in normal and atherosclerotic arteries. Activity of the isolated enzyme on low-density lipoproteins Arterioscler Thromb Vasc Biol 17 1997 300
124. 2 isoforms in human normal and atherosclerotic arterial wall Arterioscler Thromb Vasc Biol 17 1997 2257
125. 2 mRNA synthesis is stimulated by two distinct mechanisms in rat vascular smooth muscle cells FEBS Lett 261 1990 171
126. 2 in human arterial smooth muscle cells. Involvement of cell differentiation, STAT-3 activation, and modulation by other cytokines J Biol Chem 275 2000 22895
127. K. Takaki, K. Tomita, and Y. Fukushima Endogenous TNF inducibility and prognosis of colorectal cancer Anticancer Res 18 1998 4141
128. M. Muc-Wierzgon, K. Madej, M. Baranowski, and J. Wierzgon Circadian rhythmometry of serum endogenous tumor necrosis factor-α in patients with colorectal cancer metastases Eur Cytokine Netw 9 1998 193
129. F. Haverkate, S.G. Thompson, S.D. Pyke, J.R. Gallimore, and M.B. Pepys Production of C-reactive protein and risk of coronary events in stable and unstable angina. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group Lancet 349 1997 462
130. P.M. Ridker, M. Cushman, M.J. Stampfer, R.P. Tracy, and C.H. Hennekens Plasma concentration of C-reactive protein and risk of developing peripheral vascular disease Circulation 97 1998 425
131. F. Haverkate C-reactive protein as cardiovascular risk factor. A discovery by ECAT Clin Chem Lab Med 38 2000 01055
132. S.G. Thompson, J. Kienast, S.D. Pyke, F. Haverkate, and J.C. van de Loo Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group N Engl J Med 332 1995 635
133. P.M. Ridker, N. Rifai, and M.A. Pfeffer Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators Circulation 98 1998 839
134. D.J. Rader Inflammatory markers of coronary risk N Engl J Med 343 2000 1179
135. L.E. Rohde, L.H. Arroyo, and N. Rifai Plasma concentrations of interleukin-6 and abdominal aortic diameter among subjects without aortic dilatation Arterioscler Thromb Vasc Biol 19 1999 1695
136. L.E. Rohde, C.H. Hennekens, and P.M. Ridker Cross-sectional study of soluble intercellular adhesion molecule-1 and cardiovascular risk factors in apparently healthy men Arterioscler Thromb Vasc Biol 19 1999 1595
137. F. Haverkate Haemostasis factors as predictors of coronary events and their association with inflammatory reactions W. Jaross Advances in lipoprotein and atherosclerosis research: diagnostics and treatment, Proceedings of the 8th International Dresden Lipid Symposium 1995 G. Fischer, Jena Stuttgart, New York 182
138. 2 predict coronary events in patients with coronary artery disease Circulation 100 1999 1280
139. 2 in patients with unstable angina pectoris Am J Cardiol 86 2000 718
140. 2 in patients with coronary spastic angina Cardiovasc Res 47 2000 159
141. 2 in patients with coronary artery disease undergoing percutaneous coronary intervention Eur Heart J 24 2003 1824
142. 2 and the risk of future coronary artery disease in apparently healthy men and women. The EPIC-Norfolk Prospective Population Study Arterioscler Thromb Vasc Biol 25 2005 839
143. M. Naghavi, P. Libby, and E. Falk From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part I Circulation 108 2003 1664
144. 2 in T-lymphocyte activation: implication in propagation of inflammatory reaction Proc Natl Acad Sci USA 90 1993 716
145. E.E. Emeson, and A.L. Robertson Jr. T lymphocytes in aortic and coronary intimas. Their potential role in atherogenesis Am J Pathol 130 1988 369
146. G.K. Hansson, P.S. Seifert, G. Olsson, and G. Bondjers Immunohistochemical detection of macrophages and T lymphocytes in atherosclerotic lesions of cholesterol-fed rabbits Arterioscler Thromb 11 1991 745
147. 2 Biochim Biophys Acta 1005 1989 270
148. 2 reaction leads to increased monocyte adhesion of endothelial cells via the expression of adhesion molecules Eur J Biochem 217 1993 723
149. 2. A spin label study Biochim Biophys Acta 1300 1996 103
150. M. Bamberger, S. Lund-Katz, M.C. Phillips, and G.H. Rothblat Mechanism of the hepatic lipase induced accumulation of high density lipoprotein cholesterol by cells in culture Biochemistry 24 1985 3693
151. L. Blau, R. Bittman, P. Lagocki, R. Byrne, and A.M. Scanu Organization of unesterified cholesterol in high density lipoproteins probed by filipin Biochim Biophys Acta 712 1982 437
152. W.J. Johnson, F.H. Mahlberg, G.H. Rothblat, and M.C. Phillips Cholesterol transport between cells and high-density lipoproteins Biochim Biophys Acta 1085 1991 273
153. G.H. Rothblat, F.H. Mahlberg, W.J. Johnson, and M.C. Phillips Apolipoproteins, membrane cholesterol domains, and the regulation of cholesterol efflux J Lipid Res 33 1992 1091
154. 3 with endothelial cells, smooth muscle cells, and fibroblasts J Biol Chem 259 1984 13897
155. X. Collet, B. Perret, G. Simard, E. Raffai, and Y.L. Marcel Differential effects of lecithin and cholesterol on the immunoreactivity and conformation of apolipoprotein A-I in high density lipoproteins J Biol Chem 266 1991 9145
156. 2 treatment Atherosclerosis 117 1995 159
157. 2 alters the expression of selected apoB-100 epitopes and the interaction of LDL with cells J Lipid Res 29 1988 729
158. 2-modified LDL is taken up at enhanced rate by macrophages Biochem Biophys Res Commun 185 1992 465
159. 2-modified lipoproteins leads to cellular lipid accumulations Anal Cell Pathol 9 1995 113
160. R. Ross Atherosclerosis: a problem of the biology of the arterial wall cells and their interaction with blood components Arteriosclerosis 1 1981 293
161. R.E. Pitas, T.L. Innerarity, and R.B. Mahley Foam cells in explants of atherosclerotic rabbit aortas have receptors for β-very low density lipoproteins and modified low density lipoproteins Arteriosclerosis 3 1983 1
162. M.K. Jain, E.H. Cordes, and I. Phospholipases Effect of n-alkanols on the rate of enzymatic hydrolysis of egg phosphatidylcholine J Membr Biol 14 1973 101
163. M.K. Jain, and E.H. Cordes Phospholipases. II. Enzymatic hydrolysis of lecithin: effects of structure, cholesterol content, and sonication J Membr Biol 14 1973 119
164. R. Verger, and G.H. De Haas Enzyme reactions in a membrane model. 1. A new technique to study enzyme reactions in monolayers Chem Phys Lipids 10 1973 127
165. R. Verger, M.C. Mieras, and G.H. de Haas Action of phospholipase A at interfaces J Biol Chem 248 1973 4023
166. 2 and regulation of interfacial activation: hopping versus scooting Biochim Biophys Acta 1002 1989 127
167. 2-paradigm Chem Rev 101 2001 2613
168. 2 Biochim Biophys Acta 860 1986 462
169. 2 on zwitterionic and negatively charged single-chain substrates Biochemistry 24 1985 7987
170. 2 on zwitterionic and negatively charged double-chain substrates Biochemistry 24 1985 7993
171. 2 Rev Physiol Biochem Pharmacol 91 1981 91
172. 2: interfacial parameters, substrate specificities, and competitive inhibitors Biochemistry 32 1993 573
173. 2 Biochemistry 13 1974 1455
174. 2 Atherosclerosis 132 1997 165
175. 2: insight from the anion-assisted dimer Arch Biochem Biophys 433 2005 96
176. 2 (bee venom) Arch Biochem Biophys 188 1978 364
177. 2 on phosphatidylcholine bilayers. Effects of the phase transition, bilayer curvature and structural defects Biochim Biophys Acta 508 1978 185
178. 2 Biochemistry 36 1997 3870
179. M.H. Gelb, J.H. Min, and M.K. Jain Do membrane-bound enzymes access their substrates from the membrane or aqueous phase: interfacial versus non-interfacial enzymes Biochim Biophys Acta 1488 2000 20
180. 2 in intravesicle scooting mode, and heterofusion of anionic and zwitterionic vesicles Biochim Biophys Acta 860 1986 435
181. 2: monomeric enzyme is fully catalytically active at the bilayer interface Biochemistry 30 1991 7330
182. 2 on anionic vesicles in the scooting mode Biochemistry 36 1997 3216
183. 2. Electrostatically neutral interfacial surface targets zwitterionic membranes J Biol Chem 277 2002 29086
184. 2: determination of the interfacial kinetic rate constants Biochemistry 30 1991 7283
185. 2 Biochemistry 39 2000 12312
186. 2 for membranes with anionic phospholipids J Biol Chem 277 2002 48523
187. L. van Deenen, G. de Haas, and C.H. Heemskerk Hydrolysis of synthetic mixed-acid phosphatides by phospholipase A from human pancreas Biochim Biophys Acta 67 1963 295
188. M.J. Chapman Comparative analysis of mammalian plasma lipoproteins Methods Enzymol 128 1986 70
189. 2 by "lipocortins" and calpactins. An effect of binding to substrate phospholipids J Biol Chem 262 1987 1698
190. P.A. Lagocki, and A.M. Scanu In vitro modulation of the apolipoprotein composition of high density lipoprotein. Displacement of apolipoprotein A-I from high density lipoprotein by apolipoprotein A-II J Biol Chem 255 1980 3701
191. J.A. Ibdah, K.E. Krebs, and M.C. Phillips The surface properties of apolipoproteins A-I and A-II at the lipid/water interface Biochim Biophys Acta 1004 1989 300
192. J. Poensgen Are phospholipid-binding proteins in vivo phospholipase inhibitors Klin Wochenschr 67 1989 163
193. 2 of phospholipids in liposomes and cell membranes Biochim Biophys Acta 1042 1990 188
194. 2 secreted by cytokine-stimulated HepG2 cells W. Jaross al. et Advances in lipoprotein and atherosclerosis research: diagnostics and treatment, Proceedings of the 8th International Dresden Lipid Symposium 1995 G. Fischer, Jena Stuttgart, New York 86
195. 2 assay modified for serum analysis Clin Chem 39 1993 605
196. 2 and decorin in human atherosclerotic lesions Circ Res 86 2000 707
197. 2 is linked to macrophage foam cell formation J Biol Chem 277 2002 29116
198. 2s-induced modification of high-density lipoprotein linked to the reduction of its antiatherogenic functions Biochim Biophys Acta 1642 2003 129
199. 2 J Biol Chem 274 1999 11881
200. 2 but not the group IB, IIA, and V enzymes efficiently release arachidonic acid from adherent mammalian cells J Biol Chem 275 2000 3179
201. 2 has a dramatically increased ability to hydrolyze phosphatidylcholine vesicles and cell membranes Biochemistry 37 1998 13203
202. 2 hydrolysis of low-density lipoprotein results in spontaneous particle aggregation and promotes macrophage foam cell formation Arterioscler Thromb Vasc Biol 24 2004 762
203. 2 on cell membranes. Vesicle but not heparinoid binding determines rate of fatty acid release by exogenously added enzyme J Biol Chem 273 1998 32142
204. 2 Biochemistry 42 2003 7326
205. 2 by human annexin V Biochem J 329 1998 369
206. 2 Biochemistry 34 1995 13146
207. 2 induced prominent release of arachidonic acid from human myeloid leukemia cells J Biol Chem 274 1999 34203
208. 2 J Biol Chem 277 2002 48535
209. 2 receptor Arch Biochem Biophys 381 2000 31
210. 2-α J Biol Chem 279 2004 25024
211. 2 in nerve growth factor-stimulated rat serosal mast cells is facilitated by interaction with fibroblasts and mediated by a mechanism independent of their enzymatic functions J Immunol 161 1998 5008
212. 2 and peroxisome proliferator-activated receptor-α activation J Biol Chem 278 2003 29799
213. 2 gene in vascular smooth muscle cells Arterioscler Thromb Vasc Biol 25 2005 1161
214. 2α activity that is responsible for arachidonic acid release J Biol Chem 278 2003 24153
215. 2 in the human astrocytoma cell line 1321N1 J Biol Chem 273 1998 606
216. 2 in rat renal mesangial cells Biochim Biophys Acta 1348 1997 257
217. 2 receptor-involved inducible nitric oxide synthase expression J Immunol 170 2003 2093
218. 2 receptor on neutrophils and its role in elastase release and adhesion Am J Physiol Cell Physiol 283 2002 C1102
219. 2 induce beta-glucuronidase release and IL-6 production from human lung macrophages J Immunol 164 2000 4908
220. 2 induce cytokine release from blood and synovial fluid monocytes Eur J Immunol 32 2002 67
221. 2 activate selective functions in human eosinophils J Immunol 170 2003 3279
222. 2 as multivalent mediators of inflammatory and allergic disorders Int Arch Allergy Immunol 131 2003 153
223. 2 isotypes J Immunol 167 2001 4161
224. 2 on their M-type 180-kDa membrane receptor J Biol Chem 270 1995 28869
225. 2 involved in N-type receptor binding and neurotoxicity J Biol Chem 272 1997 7173
226. 2 Biochemistry 34 1995 13146
227. 2. Molecular cloning, identification of a secreted soluble form, expression, and chromosomal localization J Biol Chem 270 1995 8963
228. 2 receptor Biol Pharm Bull 27 2004 1165
229. 2 in Swiss 3T3 cells via specific binding site J Biol Chem 266 1991 19139
230. 2: specific receptors and mechanisms of action J Physiol 489 1995 29
231. 2 via specific binding sites Biochim Biophys Acta 1125 1992 210
232. 2 via its high affinity receptor stimulates extracellular matrix invasion by normal and cancer cells J Biol Chem 272 1997 2346
233. 2 Prostaglandins Other Lipid Mediat 68-69 2002 71
234. 2, in the treatment of rheumatoid arthritis J Rheumatol 32 2005 417
235. 2 activity in endothelial cell-induced modification of low density lipoprotein Proc Natl Acad Sci USA 82 1985 3000
236. 2: preferential hydrolysis of acute phase HDL J Lipid Res 39 1998 2150
237. 2 to liberate arachidonic acid Biochim Biophys Acta 1349 1997 43
238. 2 generates the novel lipid mediator lysophosphatidic acid in membrane microvesicles shed from activated cells Cell 80 1995 919
239. 2 to hydrolyze membrane phospholipids in rabbit platelets J Biochem (Tokyo) 122 1997 859
240. 2 J Biol Chem 274 1999 11494
241. 2 during early phase of apoptosis Biochim Biophys Acta 1484 2000 163
242. 2 in human erythrocytes J Biol Chem 276 2001 22732
243. 2 in arachidonic acid metabolism Adv Exp Med Biol 469 1999 183
244. A.M. Judd, K.B. Best, K. Christensen, G.M. Rodgers, and J.D. Bell Alterations in sensitivity to calcium and enzymatic hydrolysis of membranes from sickle cell disease and trait erythrocytes Am J Hematol 72 2003 162
245. 2 enzymes present in P388D1 macrophages J Biol Chem 271 1996 6758
246. E.M. Bevers, P. Comfurius, and R.F. Zwaal Regulatory mechanisms in maintenance and modulation of transmembrane lipid asymmetry: pathophysiological implications Lupus 5 1996 480
247. 2 added exogenously J Biochem (Tokyo) 110 1991 163
248. 2 Biophys J 88 2005 2692
249. 2 Blood 102 2003 2901
250. 2 induces apoptosis via a mechanism involving ceramide generation Biochim Biophys Acta 1581 2002 75
251. 2 induces neuronal cell death via apoptosis Mol Pharmacol 61 2002 114
252. 2 J Biol Chem 268 1993 839
253. 2 stimulates prostaglandin synthesis in rat liver-derived BRL-3A cells in the presence of tumor necrosis factor-α J Biochem (Tokyo) 118 1995 939
254. 2 FEBS Lett 294 1991 247
255. S.L. Schissel, X. Jiang, and J. Tweedie-Hardman Secretory sphingomyelinase, a product of the acid sphingomyelinase gene, can hydrolyze atherogenic lipoproteins at neutral pH. Implications for atherosclerotic lesion development J Biol Chem 273 1998 2738
256. 2: influence on lipoprotein metabolism J Lipid Res 38 1997 2232
257. 2 is associated with reduced concentrations of plasma cholesterol in transgenic mice Inflammation 24 2000 227
258. 2 Am J Physiol Endocrinol Metab 285 2003 E403
259. 2 group IIA Inflammation 28 2004 59
260. K. Sammalkorpi, V. Vlatonen, Y. Kerttuba, E. Nikkila, and M.R. Taskinen Changes in serum lipoprotein pattern induced by acute infection Metabolism 37 1988 859
261. X. Collet, B.P. Perret, G. Simard, C. Vieu, and L. Douste-Blazy Behaviour of phospholipase-modified HDL towards cultured hepatocytes. I. Enhanced transfers of HDL sterols and apoproteins Biochim Biophys Acta 1043 1990 301
262. 2 causes rapid catabolism and altered tissue uptake of high density lipoprotein cholesteryl ester and apolipoprotein A-I J Biol Chem 275 2000 10077
263. M. Bamberger, J.M. Glick, and G.H. Rothblat Hepatic lipase stimulates the uptake of high densitiy lipoprotein cholesterol by hepatoma cells J Lipid Res 24 1983 869
264. C. Grunfeld, and K.R. Feingold Tumor necrosis factor, interleukin, and interferon-induced changes in lipid metabolism as part of host defense Proc Soc Exp Biol Med 200 1992 224
265. R.A. Menon, K.R. Feingold, and C. Grunfeld Role of cytokines in lipid metabolism and cachexia B.B. Aggarwal R.K. Puri Human cytokines: their role in disease and therapy 1995 Blackwell Science Oxford 239
266. M.A. Noel, T.K. Smith, and W.H. Ettinger Characteristics and outcomes of hospitalized older patients who develop hypocholesterolemia J Am Geriatr Soc 39 1991 455
267. C. Alvarez, and A. Ramos Lipids, lipoproteins, and apoproteins in serum during infection Clin Chem 32 1986 142
268. G. Birke, L.A. Carlson, and S. Liljedahl Lipid metabolism and trauma: plasma lipids and lipoproteins in burns Acta Med Scand 178 1965 337
269. E.J. Coombes, P.G. Shakespeare, and G.F. Batstone Lipoprotein changes after burn injury in man J Trauma 20 1980 971
270. W.H. Ettinger, L.A. Miller, T.K. Smith, and J.S. Parks Effect of interleukin-1α on lipoprotein lipids in cynomolgus monkeys: comparison to tumor necrosis factor Biochim Biophys Acta 1128 1992 186
271. E. Windler, U. Ewers-Grabow, J. Thiery, A. Walli, D. Seidel, and H. Greten The prognostic value of hypocholesterolemia in hospitalized patients Clin Invest 72 1994 939
272. G. Shor-Posner, A. Basit, and Y. Lu Hypocholesterolemia is associated with immune dysfunction in early human immunodeficiency virus-1 infection Am J Med 94 1993 515
273. S. Winawer, B. Flehinger, and J. Buchalter Declining serum cholesterol levels before diagnosis of colon-cancer. A time-trend, case control study JAMA 263 1990 2083
274. W.H. Ettinger, and T. Harris Causes of hypocholesterolemia Coron Artery Dis 4 1993 854
275. G. Schectman, K. Sushma, R. Mueller, E.C. Borden, and A.H. Kissebah The effect of interferon on the metabolism of LDLs Arterioscler Thromb 12 1992 1053
276. S.D. Nimer, R.E. Champlen, and D.W. Gold Serum cholesterol-lowering activity of granulocyte macrophage colony stimulating factor JAMA 260 1990 3297
277. W.H. Ettinger, L.D. Miller, J.J. Albers, T.K. Smith, and J.S. Parks Lipopolysaccharide and tumor necrosis factor cause a fall in plasma concentration of lecithin: cholesterol acyltransferase in cynomolgus monkeys J Lipid Res 31 1990 1099
278. W.H. Ettinger Jr., T. Harris, R.B. Verdery, R. Tracy, and E. Kouba Evidence for inflammation as a cause of hypocholesterolemia in older people J Am Geriat Soc 43 1995 264
279. R.I. Grove, C. Mazzucco, and N. Allegretto Macrophage-derived factors increase low density lipoprotein uptake and receptor number in cultured human liver cells J Lipid Res 32 1991 1889
280. A.T. Stopeck, A.C. Nicholson, F.P. Mancini, and D.P. Hajjar Cytokine regulation of low density lipoprotein receptor gene transcription in HepG2 cells J Biol Chem 268 1993 17489
281. W.H. Ettinger, V.K. Varma, and M. Sorci-Thomas Cytokines decrease apolipoprotein accumulation in medium from HepG2 cells Arterioscler Thromb 14 1994 8
282. M. Meisner Biomarkers of sepsis: clinically useful? Curr Opin Crit Care 11 2005 473
283. 2 Arterioscl Thromb Vasc Biol 19 1999 1284
284. 2 results in increased atherosclerotic lesion size and enhanced collagen deposition J Lipid Res 46 2005 201
285. 2 results in accelerated atherogenesis by increasing oxidative stress J Lipid Res 46 2005 1604
286. 2 Lab Invest 81 2001 757
287. 2 from rabbit polymorphonuclear leukocytes. Observations on their relationship J Biol Chem 254 1979 11000
288. 2 J Clin Invest 97 1996 250
289. 2 J Clin Invest 102 1998 633
290. 2 expression and inflammation: the relationship with associated disease states J Lipid Mediat 8 1993 1
291. 2 is the principal bactericide for staphylococci and other Gram-positive bacteria in human tears Infect Immun 66 1998 2791
292. 2 J Clin Invest 95 1995 603
293. 2 Biochim Biophys Acta 1488 2000 71
294. 2 against Gram-positive bacteria J Clin Invest 103 1999 715
295. 2 Biochemistry 36 1997 14325
296. 2 in concert with polymorphonuclear leukocytes J Biol Chem 269 1994 2633
297. 2 involving both bacterial cell wall penetration and interfacial catalysis Biochim Biophys Acta 1484 2000 195
298. 2 Infect Immun 68 2000 1259
299. 2: a major physiological role for the group IIA enzyme that depends on the very high pI of the enzyme to allow penetration of the bacterial cell wall J Biol Chem 277 2002 1788
300. D.C. Angus, W.T. Linde-Zwirble, J. Lidicker, G. Clermont, J. Carcillo, and M.R. Pinsky Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care Crit Care Med 29 2001 1303
301. R.S. Watson, J.A. Carcillo, W.T. Linde-Zwirble, G. Clermont, J. Lidicker, and D.C. Angus The epidemiology of severe sepsis in children in the United States Am J Respir Crit Care Med 167 2003 695
302. D. Annane, P. Aegerter, M.C. Jars-Guincestre, and B. Guidet CUB-Rea Network. Current epidemiology of septic shock: the CUB-Rea Network Am J Respir Crit Care Med 168 2003 165
303. R.S. Hotchkiss, and I.E. Karl The pathophysiology and treatment of sepsis N Engl J Med 348 2003 138
304. M.K. Eskandari, G. Bolgos, C. Miller, D.T. Nguyen, L.E. DeForge, and D.G. Remick Anti-tumor necrosis factor antibody therapy fails to prevent lethality after cecal ligation and puncture or endotoxemia J Immunol 148 1992 2724
305. B. Echtenacher, K. Weigl, N. Lehn, and D.N. Mannel Tumor necrosis factor-dependent adhesions as a major protective mechanism early in septic peritonitis in mice Infect Immun 69 2001 3550
306. S.M. Opal, A.S. Cross, and J.W. Jhung Potential hazards of combination immunotherapy in the treatment of experimental septic shock J Infect Dis 173 1996 1415
307. C.J. Fisher Jr., J.M. Agosti, and S.M. Opal Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group N Engl J Med 334 1996 1697
308. J. Keane, S. Gershon, and R.P. Wise Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent N Engl J Med 345 2001 1098
309. G.R. Bernard, J.L. Vincent, and P.F. Laterre Recombinant human Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study group. Efficacy and safety of recombinant human activated protein C for severe sepsis N Engl J Med 344 2001 699
310. M.A. Matthay Severe sepsis - a new treatment with both anticoagulant and antiinflammatory properties N Engl J Med 344 2001 759
311. B.L. Warren, A. Eid, P. Singer KyberSept Trial Study Group Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial JAMA 286 2001 1869
312. D.E. Joyce, L. Gelbert, A. Ciaccia, B. DeHoff, and B.W. Grinnell Gene expression profile of antithrombotic protein c defines new mechanisms modulating inflammation and apoptosis J Biol Chem 276 2001 11199
313. A.P. Liappis, V.L. Kan, C.G. Rochester, and G.L. Simon The effect of statins on mortality in patients with bacteremia Clin Infect Dis 33 2001 1352
314. H. Ando, T. Takamura, T. Ota, Y. Nagai, and K. Kobayashi Cerivastatin improves survival of mice with lipopolysaccharide-induced sepsis J Pharmacol Exp Ther 294 2000 1043
315. M.W. Merx, E.A. Liehn, and U. Janssens HMG-CoA reductase inhibitor simvastatin profoundly improves survival in a murine model of sepsis Circulation 109 2004 2560
316. Y. Almog, A. Shefer, and V. Novack Prior statin therapy is associated with a decreased rate of severe sepsis Circulation 110 2004 880
317. O. Shovman, Y. Levy, B. Gilburd, and Y. Shoenfeld Antiinflammatory and immunomodulatory properties of statins Immunol Res 25 2002 271
318. K.J. Mattila, M.S. Nieminen, and V.V. Valonen Association between dental health and acute myocardial infarction Br Med J 298 1989 779
319. E. Ernst, K.L. Resch, U. Krauth, and H.F. Paulsen Does blood rheology revert to normal after myocardial infarction? Br Heart J 64 1990 248
320. V.V. Valtonen Infection as a risk factor for infarction and atherosclerosis Ann Med 23 1991 539
321. P. Saikku, M. Leinonen, and K. Mattila Serological evidence of an association of a novel Chlamydia, TWAR, with chronic coronary heart disease and acute myocardial infarction Lancet 2 1988 983
322. J.D. Rutherford Chlamydia pneumoniae and atherosclerosis Curr Atheroscler Rep 2 2000 218
323. A. Shor, C.C. Kuo, and D.L. Patton Detection of Chlamydia pneumoniae in coronary arterial fatty streaks and atheromatous plaques S Afr Med J 82 1992 158
324. C.C. Kuo, A.M. Gown, E.P. Benditt, and J.T. Grayston Detection of Chlamydia pneumoniae in aortic lesions of atherosclerosis by immuno-cytochemical stain Arterioscler Thromb 13 1993 1501
325. J.A. Ramirez Isolation of Chlamydia pneumoniae from the coronary artery of a patient with coronary atherosclerosis. The Chlamydia pneumoniae/ Atherosclerosis Study Group Ann Intern Med 125 1996 979
326. J.B. Muhlestein Secondary prevention of coronary artery disease with antimicrobials: current status and future directions Am J Cardiovasc Drugs 2 2002 107
327. C. Ouyang, C.M. Teng, and T.F. Huang Characterization of snake venom components acting on blood coagulation and platelet function Toxicon 30 1992 945
328. 2 enzymes: structure, function and mechanism 1997 Wiley New York 353
329. 2 on blood plasma and on a cell-free system is due to a phospholipid-independent mechanism of action involving the inhibition of factor Va Eur J Biochem 237 1996 778
330. 2 has anticoagulant activity in vitro on human plasma Thromb Res 70 1993 337
331. 2 on cell-free prothrombinase complex J Biol Chem 269 1994 26338
332. 2 inhibits platelet aggregation in vitro and in vivo in rat and guinea pig Eur J Pharmacol 252 1994 147
333. 2 from Naja nigricollis venom inhibits the prothrombinase complex by a novel nonenzymatic mechanism Biochemistry 29 1990 7742
334. 2 involves binding to factor Xa J Biol Chem 273 1998 23764
335. 2 from Naja nigricollis venom binds to coagulation factor Xa to inhibit the prothrombinase complex Arch Biochem Biophys 369 1999 107
336. 2 Eur J Biochem 267 2000 4960
337. B. Dixon The role of microvascular thrombosis in sepsis Anaesth Intensive Care 32 2004 619
338. 2 in atherosclerosis: 2. Potential involvement of biologically active oxidized phospholipids Arterioscler Thromb Vasc Biol 19 1999 1291
339. R. Labeque, C.J. Mullon, J.P. Ferreira, R.S. Lees, and R. Langer Enzymatic modification of plasma low density lipoproteins in rabbits: a potential treatment for hypercholesterolemia Proc Natl Acad Sci USA 90 1993 3476
340. S.D. Shefer, J. Ferreira, C.J. Mullon, and R. Langer Extracorporeal enzymatic removal of low density lipoproteins in rabbits: efficacy and safety Int J Artif Organs 16 1993 218
341. J. Groen, B.K. Tjiong, and C.E. Kamminga The influence of nutrition, individuality and some other factors, including various forms of stress, on the serum cholesterol: an experiment of nine months duration in 60 normal human volunteers Voeding 13 1952 556
342. A. Rigotti, E.R. Edelman, and P. Seifert Regulation by adrenocorticotropic hormone of the in vivo expression of scavenger receptor class B type I (SR-BI), a high density lipoprotein receptor, in steroidogenic cells of the murine adrenal gland J Biol Chem 271 1996 33545
343. 2 generates anti-apoptotic survival signals in kidney fibroblasts J Biol Chem 274 1999 27726
344. R.S. Hotchkiss, R.E. Schmieg Jr., and P.E. Swanson Rapid onset of intestinal epithelial and lymphocyte apoptotic cell death in patients with trauma and shock Crit Care Med 28 2000 3207
345. + T lymphocytes in humans J Immunol 166 2001 6952
346. D.W. Gilroy, T. Lawrence, M. Perretti, and A.G. Rossi Inflammatory resolution: new opportunities for drug discovery Nat Rev Drug Discov 3 2004 401
347. D.W. Gilroy, A. Tomlinson, and D.A. Willoughby Differential effects of inhibitors of cyclooxygenase (cyclooxygenase 1 and cyclooxygenase 2) in acute inflammation Eur J Pharmacol 355 1998 211
348. D.W. Gilroy, P.R. Colville-Nash, D. Willis, J. Chivers, M.J. Paul-Clark, and D.A. Willoughby Inducible cyclooxygenase may have anti-inflammatory properties Nat Med 5 1999 698
349. 2 Proc Natl Acad Sci USA 95 1998 7951
350. 2-cyclooxygenase pathways in inflammation J Leukoc Biol 66 1999 535
351. 2 up-regulates cyclooxygenase-2 and amplifies cytokine-mediated prostaglandin production in human rheumatoid synoviocytes J Immunol 165 2000 2790
352. 2 isoforms in the checkpoint control of acute inflammation FASEB J 18 2004 489
353. 2 activity and protein synthesis is blocked by dexamethasone in rat mesangial cells FEBS Lett 333 1993 339
354. A. Munck, P.M. Guyre, and N.J. Holbrook Physiological functions of glucocorticoids in stress and their relation to pharmacological actions Endocr Rev 5 1984 25
355. C.N. Serhan Lipoxin biosynthesis and its impact in inflammatory and vascular events Biochim Biophys Acta 1212 1994 1
356. B.D. Levy, C.B. Clish, B. Schmidt, K. Gronert, and C.N. Serhan Lipid mediator class switching during acute inflammation: signals in resolution Nat Immunol 2 2001 612
357. C. Godson, S. Mitchell, K. Harvey, N.A. Petasis, N. Hogg, and H.R. Brady Cutting edge: lipoxins rapidly stimulate nonphlogistic phagocytosis of apoptotic neutrophils by monocyte-derived macrophages J Immunol 164 2000 1663
358. F. Bussolino, E. Fischer, F. Turrini, M.D. Kazatchkine, and P. Arese Platelet-activating factor enhances complement-dependent phagocytosis of diamide-treated erythrocytes by human monocytes through activation of protein kinase C and phosphorylation of complement receptor type one (CR1) J Biol Chem 264 1989 21711
359. M. Ichinose, N. Hara, M. Sawada, and T. Maeno A flow cytometric assay reveals an enhancement of phagocytosis by platelet activating factor in murine peritoneal macrophages Cell Immunol 156 1994 508
360. 2 isozymes with a potential role in atherosclerosis Curr Opin Lipidol 14 2003 431
361. 2 gene by cAMP and interleukin-1β in vascular smooth muscle cells: interplay of the CCAAT/enhancer binding protein (C/EBP), nuclear factor-κB and Ets transcription factors Biochem J 368 2002 415
362. 2 gene transcription involves C/EBP-β and -δ in vascular smooth muscle cells Arterioscler Thromb Vasc Biol 20 2000 2559
363. 2 gene in rat smooth-muscle cells Biochem J 376 2003 351
364. 2 production by blocking mRNA synthesis and post-transcriptional expression J Biol Chem 265 1990 12745
365. 2 expression in human aortic smooth muscle and HepG2 hepatoma cells FEBS Lett 577 2004 81
366. 2 expression in interleukin-1β-stimulated rat neonatal cardiomyocytes J Biol Chem 276 2001 43842
367. 2 expression in guinea-pig alveolar macrophages: a possible involvement of camp Biochem J 330 1998 89
368. 2-IIA expression in alveolar macrophages through NF-κB and PPAR-γ-dependent pathways Mol Pharmacol 61 2002 786
369. 2-type IIA by protein kinase C in rat renal mesangial cells Biochem Pharmacol 58 1999 1751
370. 2 expression in rat renal mesangial cells Biochim Biophys Acta 1391 1998 213
371. 2 and inducible NO-synthase in rat renal mesangial cells Br J Pharmacol 127 1999 51
372. 2 expression via generation of reactive oxygen species in tumor necrosis factor-α-stimulated mesangial cells Cell Signal 16 2004 967
373. 2 from human articular chondrocytes J Rheumatol 22 1995 2114
374. 2 gene expression in rabbit articular chondrocytes J Clin Invest 99 1997 1864
375. 2 Lab Invest 76 1997 171
376. 2, and cyclooxygenase-2 by peptide growth factors Biochim Biophys Acta 1403 1998 47
377. 2 activation in human neuroblasts Biochem J 294 1993 893
378. 2 in immortalized astrocytes (DITNC): response to genistein and pyrrolidine dithiocarbamate J Interferon Cytokine Res 19 1999 121
379. 2 in immortalized astrocytes (DITNC) Neurochem Res 25 2000 613
380. 2 in mouse epidermal keratinocytes J Lipid Res 39 1998 569
381. 2 and the acute-phase proteins haptoglobin (HP) and alpha1-anti-chymotrypsin (ACH) by HepG2 cells Clin Exp Immunol 108 1997 175
382. 2 gene expression in human hepatoma cells Cytokine 9 1997 199
383. 2 promoter in HepG2 cells: possible role of single-strand binding proteins Mol Cell Biol 17 1997 4238